- Sirona Biochem (SBM) announced positive results of the clinical safety study for its novel anti-aging compound, FC-1326
- 100 people aged 18 to 70 took part in the study to confirm that the application of the product does not induce delayed contact sensitization and to assess the skin compatibility of the formulation
- The results of the study are necessary to move to the efficacy clinical trial, which is scheduled to start in early December 2022
- Sirona Biochem (SBM) is down 12.50 per cent, trading at $0.10 per share as of 10:05 am ET
Sirona Biochem (SBM) announced positive results of the clinical safety study for its novel anti-aging compound.
FC-1326 has been proven to be a non-irritant and non-sensitizer.
Sirona’s lead anti-aging compound will soon enter a clinical trial designed to assess its potential to reverse the effects of aging on facial skin, restoring lost volume and reducing fine wrinkles.
100 people aged 18 to 70 took part in the study. The main goal of the test was to confirm that the application of the product does not induce delayed contact sensitization and to assess the skin compatibility of the formulation. It did not cause irritation, sensitization, or allergy in any subject.
The results of the study are necessary to move to the efficacy clinical trial, which is scheduled to start in early December 2022.
Sirona Biochem is a cosmetic ingredient and drug discovery company specializing in stabilizing carbohydrate molecules to improve efficacy and safety. Its compounds are licensed to leading companies around the world.
Sirona Biochem (SBM) is down 12.50 per cent, trading at $0.10 per share as of 10:05 am ET.
